Table 1.
Patient demographics and characteristics of the dominant unit in engraftment* (n = 157).
| Characteristics | CMV+ (n = 85) | CMV- (n = 72) | All patients (n = 157) |
|---|---|---|---|
| Median age (range), years | 47 (1-69) | 33 (0.9-61) | 39 (0.9-69) |
| Median weight (range), kg | 67 (10-111) | 69 (8-125) | 67 (8-125) |
| Diagnosis, n (%) | |||
| Acute myeloid leukemia | 33 (39%) | 20 (28%) | 53 (34%) |
| Acute lymphoblastic leukemia | 17 (20%) | 18 (25%) | 35 (22%) |
| Other acute leukemia, MDS or CML | 5 (6%) | 8 (11%) | 13 (8%) |
| Lymphoma or CLL | 30 (35%) | 26 (36%) | 56 (36%) |
| Preparative regimen*, n (%) | |||
| Myeloablative | 62 (73%) | 59 (82%) | 121 (77%) |
| Non-myeloablative | 23 (27%) | 13 (18%) | 36 (23%) |
| HLA-match** | |||
| 6/6 | - | 6 | 6 |
| 5/6 | 46 | 36 | 82 |
| 4/6 | 39 | 30 | 69 |
| Median (range) 10 allele | 6/10 (2-9/10) | 6/10 (2-9/10) | 6/10 (2-9/10) |
| Median (range) inf. cell dose** | |||
| Infused TNC × 107/kg | 2.2 (1.2-12.7) | 2.3 (1.3-11.3) | 2.2 (1.2-12.7) |
| Infused CD34+ cells × 105/kg | 0.9 (0.2-6.9) | 1.0 (0.1-4.7) | 1.0 (0.1-6.9) |
CMV indicates cytomegalovirus; + or - indicates recipient CMV serostatus positive or negative respectively; kg, kilogram; n, number; MDS, myelodysplasia; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; HLA, human leukocyte antigen; inf., infused; TNC, total nucleated cell.
Myeloablative regimens included high dose 1320-1375 cGy total body irradiation based regimens (n = 50), high dose chemotherapy-based (n = 17, predominantly Clo/Mel/Thio), or reduced intensity but functionally myeloablative regimens (n = 56 including 47 Cy/Flu/Thio/TBI400, 8 Mel/Flu, 1 other). Non-myeloablative conditioning was Cy/Flu/TBI200 (n = 34).
Unit dominating in hematopoiesis based on blood and/or bone marrow chimerism analyses irrespective of success of clinical neutrophil engraftment.